Najib Bouz, MD
Obstetrics/Gynecology · Glendora
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 54 years
- Graduated 1972
Offices
2 locations · Emanate Health Medical Care Foundation · 85 clinicians in this group
Hospitals listed: Emanate Health Foothill Presbyterian Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bouz’s office at (626) 963-4124 to ask if they take your plan before you enroll.
California Medical Board record
Licence A32244 · Current
Licensed to practise in California · since 1978 · expires 2028-01-31 · University of Damascus Faculty of Medicine. Board flags: Malpractice Judgment.
Public record actions
| 1999-04-16 | Malpractice judgment | $2,789,117 · Lasc/burbank · FC023205 |
Surgery centers they own
- Glendora Surgery Center, Inc.Ambulatory Surgery Center · Glendora, CA47.5% owner since 2003 · accredited by AAAHCAccreditation Renewed6 inspections, 2 with deficiencies · last 2024-06-03: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Emanate Health Foothill Presbyterian HospitalGlendora, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency departmentPart of Emanate Health, which runs 3 hospitalsPatients rate it 2 of 5 · 63% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Emanate Health Foothill Presbyterian Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2) · 475 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.74 to 1.58) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 108 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 64 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.7 · 1,404 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.51) · 2,452 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.57 (1.08 to 6.06) · 286 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.51 (0.83 to 4.19) · 283 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.99 (1.35 to 20.62) · 77 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.86 (1.63 to 10.08) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.97 (0.06 to 1.88) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.662 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.026 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 44 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 234 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.2 · 139 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 308 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.1 · 520 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 85 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9 to 16.2) · 293 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 174 cases | No different | Jan 2024 – Dec 2024 |
What patients said (582 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 52% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 65% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$10,382
Medicare paid this office $10,382 for 57 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 14 | $2,234 | $106 |
| Short return visit (20+ min) | 15 | $1,878 | $75 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 31 | $1,313 | $42 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 16 | $789 | $49 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
57 Original Medicare patients in 2024. Average age 71 · Women 100% · Also on Medicaid 26% · Health risk score 1.16. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 63% · Diabetes 37% · Coronary heart disease 23% · Depression 19%.
The office billed $36,636, Medicare allowed $12,577 and paid $10,382; for 133 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 57 | 133 | 71 | 1.16 | $36,636 | $10,382 |
| 2023 | 79 | 185 | 72 | 0.91 | $62,206 | $18,036 |
| 2022 | 108 | 233 | 70 | 0.88 | $68,357 | $18,985 |
| 2021 | 115 | 265 | 70 | 0.74 | $91,428 | $25,592 |
| 2020 | 80 | 190 | 70 | 0.89 | $60,454 | $17,061 |
| 2019 | 181 | 410 | 69 | 0.92 | $102,950 | $41,281 |
| 2018 | 199 | 485 | 69 | 0.89 | $109,390 | $43,643 |
| 2017 | 196 | 414 | 69 | 1.05 | $102,620 | $41,925 |
| 2016 | 190 | 498 | 68 | 1.02 | $97,093 | $43,566 |
| 2015 | 195 | 512 | 68 | 1.05 | $103,997 | $44,984 |
| 2014 | 277 | 575 | 69 | 1.02 | $123,296 | $49,070 |
| 2013 | 220 | 483 | 68 | 1.12 | $92,406 | $41,809 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Screening mammography | 25 | $3,767 | $151 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 18 | $3,286 | $183 |
| Short return visit (20+ min) | 25 | $2,045 | $76 |
| Return visit (30+ min) | 12 | $1,322 | $94 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 25 | $1,247 | $50 |
| Dxa bone density measurement of hip, pelvis, spine | 22 | $982 | $45 |
2022: 7 services
| Screening mammography | 48 | $7,189 | $150 |
| Complete ultrasound scan of 1 breast | 12 | $1,793 | $75 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 12 | $1,377 | $98 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 28 | $1,368 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 29 | $1,261 | $43 |
| Short return visit | 17 | $1,000 | $43 |
| Dxa bone density measurement of hip, pelvis, spine | 20 | $861 | $43 |
2021: 7 services
| Screening mammography | 60 | $9,225 | $154 |
| Complete ultrasound scan of 1 breast | 21 | $3,807 | $93 |
| Short return visit (20+ min) | 19 | $2,226 | $67 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 12 | $1,781 | $111 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 28 | $1,384 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 29 | $1,272 | $44 |
| Dxa bone density measurement of hip, pelvis, spine | 15 | $665 | $44 |
2020: 5 services
| Screening mammography | 42 | $6,750 | $161 |
| Short return visit (20+ min) | 26 | $1,911 | $56 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 20 | $991 | $50 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $943 | $45 |
| Dxa bone density measurement of hip, pelvis, spine | 17 | $785 | $46 |
2019: 9 services
| Screening mammography | 98 | $15,244 | $156 |
| Complete ultrasound scan of 1 breast | 43 | $5,896 | $120 |
| Short return visit (20+ min) | 50 | $3,602 | $55 |
| Dxa bone density measurement of hip, pelvis, spine | 39 | $1,786 | $46 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 36 | $1,758 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 36 | $1,543 | $43 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | $1,535 | $128 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,176 | $90 |
| Complete ultrasound scan of pelvis | 12 | $1,166 | $97 |
2018: 8 services
| Screening mammography | 108 | $16,509 | $153 |
| Complete ultrasound scan of 1 breast | 44 | $6,389 | $125 |
| Short return visit (20+ min) | 51 | $4,807 | $53 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 55 | $2,664 | $48 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 55 | $2,236 | $41 |
| Dxa bone density measurement of hip, pelvis, spine | 47 | $2,195 | $47 |
| Diagnostic mammography of 1 breast | 13 | $1,437 | $111 |
| Complete ultrasound scan of pelvis | 13 | $1,273 | $91 |
2017: 7 services
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 112 | $16,771 | $150 |
| Complete ultrasound scan of 1 breast | 36 | $4,448 | $114 |
| Short return visit (20+ min) | 39 | $4,407 | $54 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 23 | $2,836 | $123 |
| Dxa bone density measurement of hip, pelvis, spine | 46 | $2,078 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 26 | $1,264 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 27 | $1,106 | $41 |
2016: 9 services
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 73 | $10,754 | $147 |
| Short return visit (20+ min) | 65 | $5,792 | $53 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 71 | $3,472 | $49 |
| Complete ultrasound scan of 1 breast | 21 | $2,978 | $115 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 71 | $2,905 | $41 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 20 | $2,476 | $124 |
| Complete ultrasound scan of pelvis | 17 | $1,412 | $83 |
| New patient visit (30+ min) | 18 | $1,373 | $76 |
| Dxa bone density measurement of hip, pelvis, spine | 26 | $1,179 | $45 |
2015: 9 services
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 76 | $11,325 | $149 |
| Short return visit (20+ min) | 60 | $6,919 | $57 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 37 | $4,648 | $126 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 50 | $2,474 | $49 |
| Complete ultrasound scan of 1 breast | 16 | $2,333 | $101 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 55 | $2,276 | $41 |
| Complete ultrasound scan of pelvis | 19 | $1,856 | $84 |
| Dxa bone density measurement of hip, pelvis, spine | 35 | $1,604 | $46 |
| New patient visit (30+ min) | 12 | $986 | $82 |
2014: 9 services
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 66 | $9,883 | $150 |
| Short return visit (20+ min) | 66 | $7,049 | $59 |
| Dxa bone density measurement of hip, pelvis, spine | 124 | $6,822 | $55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 25 | $3,059 | $122 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 53 | $2,592 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 55 | $2,247 | $41 |
| Complete ultrasound scan of pelvis | 18 | $1,883 | $99 |
| Ultrasound of breasts | 13 | $1,303 | $87 |
| New patient visit (30+ min) | 12 | $896 | $75 |
2013: 8 services
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 67 | $10,323 | $154 |
| Short return visit (20+ min) | 65 | $6,950 | $56 |
| Dxa bone density measurement of hip, pelvis, spine | 55 | $3,079 | $56 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 56 | $2,814 | $50 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 23 | $2,779 | $121 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 56 | $2,297 | $41 |
| Complete ultrasound scan of pelvis | 14 | $1,631 | $102 |
| Ultrasound of breasts | 13 | $803 | $62 |
Medicaid work
$0 in 2024
Medicaid paid $0 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $0 |
| 2024 | 12 | 1 | 12 | $0 |
| 2021 | 25 | 1 | 12 | $189 |
| 2020 | 12 | 1 | 12 | $72 |
| 2019 | 15 | 1 | 12 | $299 |
See the largest Medicaid services in earlier years
2021
| Short return visit (20+ min) | 25 | $189 |
2020
| Short return visit (20+ min) | 12 | $72 |
2019
| Short return visit (20+ min) | 15 | $299 |
Drugs they prescribed that Part D paid
$26,822
Pharmacies billed $26,822 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
242 generic and 33 brand-name prescriptions · $26,822 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 100 | $3,898 | $39 |
| Clobetasol Propionate | 11 | $484 | $44 |
| Progesterone | 14 | $481 | $34 |
| Alendronate | 42 | $161 | $4 |
| Nystatin-Triamcinolone | 11 | $93 | $8 |
Year by year
| 2024 | 275 | 89 | None | 12% | $26,822 |
| 2023 | 273 | 82 | None | 22% | $37,827 |
| 2022 | 275 | 73 | None | 21% | $32,869 |
| 2021 | 266 | 79 | None | 18% | $29,677 |
| 2020 | 285 | 85 | None | None | $38,932 |
| 2019 | 377 | 98 | 3% (12) | None | $39,260 |
| 2018 | 328 | 114 | None | 25% | $31,842 |
| 2017 | 397 | 107 | None | 21% | $31,548 |
| 2016 | 504 | 147 | 3% (16) | 24% | $40,429 |
| 2015 | 377 | 116 | 5% (18) | 32% | $36,489 |
| 2014 | 403 | 124 | 5% (20) | None | $34,852 |
| 2013 | 320 | 97 | None | None | $24,064 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Estradiol | 82 | $5,741 | $70 |
| Prempro | 16 | $4,662 | $291 |
| Progesterone | 16 | $558 | $35 |
| Alendronate | 35 | $306 | $9 |
| Valacyclovir | 14 | $236 | $17 |
| Medroxyprogesterone Acetate | 11 | $166 | $15 |
2022: 6 drugs
| Myrbetriq | 16 | $10,445 | $653 |
| Prempro | 16 | $5,729 | $358 |
| Estradiol | 74 | $4,085 | $55 |
| Rosuvastatin | 16 | $748 | $47 |
| Valacyclovir | 19 | $271 | $14 |
| Alendronate | 37 | $265 | $7 |
2021: 5 drugs
| Estradiol | 59 | $4,939 | $84 |
| Premphase | 11 | $2,511 | $228 |
| Raloxifene | 18 | $1,117 | $62 |
| Alendronate | 35 | $462 | $13 |
| Valacyclovir | 16 | $178 | $11 |
2020: 8 drugs
| Premarin | 28 | $9,005 | $322 |
| Estradiol | 48 | $5,084 | $106 |
| Premphase | 11 | $2,365 | $215 |
| Progesterone | 12 | $974 | $81 |
| Raloxifene | 15 | $746 | $50 |
| Valacyclovir | 14 | $276 | $20 |
| Alendronate | 27 | $176 | $7 |
| Fluconazole | 11 | $79 | $7 |
2019: 9 drugs
| Myrbetriq | 23 | $9,895 | $430 |
| Premarin | 27 | $7,777 | $288 |
| Estradiol | 55 | $4,307 | $78 |
| Premphase | 12 | $2,486 | $207 |
| Ibandronate | 18 | $929 | $52 |
| Rosuvastatin | 12 | $738 | $62 |
| Valacyclovir | 13 | $295 | $23 |
| Fluconazole | 14 | $166 | $12 |
| Alendronate | 26 | $158 | $6 |
2018: 7 drugs
| Premarin | 12 | $4,574 | $381 |
| Myrbetriq | 11 | $3,839 | $349 |
| Estradiol | 44 | $2,793 | $63 |
| Raloxifene | 19 | $1,438 | $76 |
| Nitrofurantoin Mono-Macro | 12 | $272 | $23 |
| Fluconazole | 21 | $135 | $6 |
| Atorvastatin | 18 | $127 | $7 |
2017: 8 drugs
| Premarin | 11 | $4,111 | $374 |
| Premphase | 12 | $2,130 | $178 |
| Estradiol | 38 | $1,610 | $42 |
| Oxybutynin Chloride Er | 18 | $584 | $32 |
| Progesterone | 12 | $352 | $29 |
| Alendronate | 16 | $261 | $16 |
| Atorvastatin | 18 | $173 | $10 |
| Fluconazole | 15 | $138 | $9 |
2016: 11 drugs
| Procrit | 32 | $8,149 | $255 |
| Premarin | 20 | $4,232 | $212 |
| Raloxifene | 26 | $2,818 | $108 |
| Nystatin-Triamcinolone | 17 | $2,096 | $123 |
| Estradiol | 50 | $1,701 | $34 |
| Progesterone | 21 | $963 | $46 |
| Oxybutynin Chloride Er | 16 | $610 | $38 |
| Alendronate | 18 | $310 | $17 |
| Atorvastatin | 24 | $309 | $13 |
| Fluconazole | 19 | $291 | $15 |
| Nitrofurantoin Mono-Macro | 11 | $281 | $26 |
2015: 10 drugs
| Raloxifene | 31 | $5,648 | $182 |
| Clobetasol Propionate | 19 | $4,492 | $236 |
| Premarin | 19 | $3,494 | $184 |
| Prempro | 17 | $2,729 | $161 |
| Nystatin-Triamcinolone | 15 | $1,966 | $131 |
| Estradiol | 30 | $1,064 | $35 |
| Progesterone | 13 | $510 | $39 |
| Alendronate | 22 | $154 | $7 |
| Isosorbide Mononitrate Er | 12 | $131 | $11 |
| Fluconazole | 11 | $115 | $10 |
2014: 11 drugs
| Raloxifene | 15 | $4,061 | $271 |
| Prempro | 27 | $3,029 | $112 |
| Premarin | 15 | $2,834 | $189 |
| Vesicare | 12 | $2,663 | $222 |
| Clobetasol Propionate | 25 | $1,806 | $72 |
| Vivelle-Dot | 13 | $1,286 | $99 |
| Ibandronate | 11 | $1,162 | $106 |
| Alendronate | 28 | $245 | $9 |
| Estradiol | 28 | $197 | $7 |
| Warfarin | 14 | $118 | $8 |
| Fluconazole | 11 | $95 | $9 |
2013: 9 drugs
| Evista | 12 | $5,878 | $490 |
| Vesicare | 17 | $3,485 | $205 |
| Prempro | 26 | $2,530 | $97 |
| Ibandronate | 14 | $1,480 | $106 |
| Nystatin-Triamcinolone | 11 | $1,258 | $114 |
| Vivelle-Dot | 13 | $967 | $74 |
| Clobetasol Propionate | 12 | $315 | $26 |
| Estradiol | 49 | $302 | $6 |
| Alendronate | 18 | $230 | $13 |
Money from drug and device companies
$277 in 2023
| 2023 | 3 | 4 | None | $277 |
| 2022 | 7 | 7 | None | $263 |
| 2021 | 5 | 13 | None | $278 |
| 2020 | 5 | 6 | None | $136 |
| 2019 | 8 | 13 | None | $415 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merz North America | Xeomin | $231 | 2 payments
|
| AbbVie | Orilissa | $26 | 1 payment
|
| Hologic Sales and Service | Acessa Provu System | $19 | 1 payment
|
See all 4 published payments
| Merz North America | Meals · 2023-12-15 | Xeomin | $31 |
| Hologic Sales and Service | Meals · 2023-11-30 | Acessa Provu System | $19 |
| Merz North America | Meals · 2023-11-07 | None | $200 |
| AbbVie | Meals · 2023-11-07 | Orilissa | $26 |
See earlier years (2022, 2021, 2020, 2019)
2022: $263
| Stryker | Mako | $161 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $21 | 1 payment
|
| Boston Scientific | Superion Indirect Decompression System | $20 | 1 payment
|
| CooperSurgical | Paragard | $16 | 1 payment
|
| Allergan | None | $15 | 1 payment
|
| Abbvie | Oriahnn | $15 | 1 payment
|
| Myovant Sciences | Myfembree | $14 | 1 payment
|
2021: $278
| AbbVie | Orilissa | $183 | 7 payments
|
| Myovant Sciences | Myfembree | $28 | 2 payments
|
| Allergan | Botox | $24 | 2 payments
|
| Hologic | Acessa Provu System | $23 | 1 payment
|
| Ethicon US | Ethicon | $21 | 1 payment
|
2020: $136
| DySIS Medical | Ultra 2.0 | $42 | 1 payment
|
| AbbVie | Oriahnn | $40 | 2 payments
|
| Hologic | Novasure | $23 | 1 payment
|
| Allergan | Botox Cosmetic | $18 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Mirena | $13 | 1 payment
|
2019: $415
| AbbVie | Orilissa | $258 | 3 payments
|
| Amgen | Evenity | $40 | 2 payments
|
| Pfizer | Premarin | $31 | 2 payments
|
| CooperSurgical | Paragard | $19 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $18 | 1 payment
|
| Hologic | Novasure | $17 | 2 payments
|
| Duchesnay USA | Osphena | $17 | 1 payment
|
| Minerva Surgical | Endometrial Ablation System (Device) | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 79.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1265434591
- Licence
- CA A32244California A32244: Current · expires 2028-01-31
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 315 E Route 66, Glendora, CA, 91740
- NPI first listed
- 2005-05-31
- NPI last updated
- 2024-01-30
- NPI record certified
- 2024-01-30
This is when the NPI record was last certified, not a medical board exam.